Chemical Review and Letters

A review on the cannabinoids impacts on psychiatric disorders

Document Type : Review Article

Authors

Sajedeh Rabipour 1
Evan Abdulkareem Mahmood 2
Maryam Afsharkhas 3
Vahideh Abbasi 4

1 School of medicine, Iran university of medical science, Tehran, Iran

2 Medical Laboratory Sciences Department, College of Health Sciences, University of Human Development, Sulaymaniyah, Iraq

3 School of Medicine, Iran university of medical science, Tehran, Iran

4 Department of Chemistry, University of Zanjan, Zanjan, Iran

https://doi.org/10.22034/crl.2022.349864.1175
Abstract
Psychiatric adverse effects of cannabis are mainly due to psychotic symptoms. In addition, it's one of the most used drugs by patients with severe mental disorders. Cannabis dependence must therefore be treated concurrently with the mental disorder it often coexists with. Cannabis dependence is treated with motivational strategies and cognitive-behavioral techniques. These techniques have proven superior to the techniques used in control groups, despite low adherence to treatment and frequent relapses. Data from clinical trials are scarce for pharmacological interventions. Other useful drugs have been investigated for mental and addictive disorders, often with negative results; on the other hand, there are drugs that specifically act on cannabinoids. The most successful trials have been conducted with cannabinoid antagonists, phytocannabinoid extracts, nabilone and, mainly, dronabinol. Few clinical trials exist regarding the treatment of comorbid mental disorders. A typical antipsychotics for mania, and anticonvulsants for maintenance treatment of bipolar disorder are recommended by observational studies and published case reports in these patients. In animal experiments, the cannabinoid system is suggested as a possible therapeutic target for treating depression and anxiety symptoms in patients with this dual condition. To treat psychosis and dependence, both approaches must be employed. In this population, cognitive-behavioral therapy and motivational strategies have proved effective. Despite little research on cannabis consumption, clinical cases indicate that cannabis abstinence is an important factor in the progression of psychosis and that most clinicians choose atypical antipsychotics for the management of these conditions.

Keywords

Cannabis
Comorbidity
Treatment
Psychosis
Mood disorders
Anxiety

Subjects

  • Gates P, Copeland J, Swift W, Martin G. Barriers and facilitators to cannabis treatment. Drug Alcohol Rev. 2011.
  • Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and signifi cance of cannabis withdrawal syndrome. Am J Psychiatry. 2004;161:1967-77.
  • Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol. 2000;68:898-908.
  • Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat. 2001;21:55-64.
  • Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol. 2006;74: 307-16.
  • Martin G, Copeland J, Swift W. The Adolescent Cannabis Check-Up: feasibility of a brief intervention for young cannabis users. J Subst Abuse Treat. 2005;29:207-13.
  • Hendriks V, Van der Schee E, Blanken P. Treatment of adolescents with a cannabis use disorder: main fi ndings of a randomized controlled trial comparing multidimensional family therapy and cognitive behavioral therapy in The Netherlands. Drug Alcohol Depend. 2011;119:64-71.
  • Walker DD, Stephens R, Roffman R, Demarce J, Lozano B, Towe S, et al. Randomized controlled trial of motivational enhancement therapy with nontreatment-seeking adolescent cannabis users: a further test of the teen marijuana check-up. Psychol Addict Behav. 2011;25:474-84.
  • Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: fi ndings from a randomized multisite trial. J Consult Clin Psychol. 2004;72:455-66.
  • Dennis M, Godley SH, Diamond G, Tims FM, Babor T, Donaldson J, et al. The Cannabis Youth Treatment (CYT) Study: main fi ndings from two randomized trials. J Subst Abuse Treat. 2004; 27:197-213.
  • Denis C, Lavie E, Fatséas M, Auriacombe M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev. 2006;3:CD005336.
  • McRae AL, Brady KT, Carter RE. Buspirone for treatment of marijuana dependence: a pilot study. Am J Addict. 2006;15:404.
  • Cornelius JR, Salloum IM, Haskett RF, Ehler JG, Jarrett PJ, Thase ME, et al. Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav. 1999;24:111-4.
  • Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacol (Berl). 2001;155:171-9.
  • Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacol (Berl). 2003;165:157-65.
  • Levin FR, McDowell D, Evans SM, Nunes E, Akerele E, Donovan S, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict. 2004;13:21-32.
  • Bowen R, McIlwrick J, Baetz M, Zhang X. Lithium and marijuana withdrawal. Can J Psychiatry. 2005;50:240-1.
  • Winstock AR, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol. 2009;23:84-93.
  • Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacol (Berl). 2003;166:77-85.
  • Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010;35:1879-85.
  • Lile JA, Kelly TH, Hays LR. Separate and combined effects of the cannabinoid agonists nabilone and D9-THC in humans discriminating D9-THC. Drug Alcohol Depend. 2011;116:86-92.
  • Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86:22-9.
  • Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubarán C, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29:158-70.
  • Levin FR, Kleber HD. Use of dronabinol for cannabis dependence: two case reports and review. Am J Addict. 2008;17:161-4.
  • Dannon PN, Lowengrub K, Amiaz R, Grunhaus L, Kotler M. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum Psychopharmacol. 2004;19:97-101.
  • Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010;112:39-45.
  • Arias F, Ramos JA (coordinadores). Aspectos psiquiátricos del consumo de cannabis: Casos clínicos. Madrid: Sociedad Española de Investigación en Cannabinoides; 2008.
  • Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology. 2009;56 Suppl 1:235-43.
  • Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophreniaspectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005;187:510-5.
  • Saddichha S, Sur S, Sinha BN, Khess CR. How is substance use linked to psychosis? A study of the course and patterns of substance dependence in psychosis. Subst Abus. 2010;31:58-67.
  • Wisdom JP, Manuel JI, Drake RE. Substance use disorder among people with fi rst-episode psychosis: a systematic review of course and treatment. Psychiatr Serv. 2011;62:1007-12.
  • Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010;167:987-93.
  • González-Pinto A, Alberich S, Barbeito S, Gutiérrez M, Vega P, Ibáñez B, et al. Cannabis and fi rst-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull. 2011;37:631-9.
  • Sokolski KN, Cummings JL, Abrams BI, DeMet EM, Katz LS, Costa JF. Effects of substance abuse on hallucination rates and treatment responses in chronic psychiatric patients. J Clin Psychiatry. 1994;55:380-7.
  • Kumra S, Thaden E, DeThomas C, Kranzler H. Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. Schizophr Res. 2005;73:369-71.
  • Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res. 2009;113:138-44.
  • Bonsack C, Gibellini Manetti S, Favrod J, Montagrin Y, Besson J, Bovet P, et al. Motivational intervention to reduce cannabis use in young people with psychosis: a randomized controlled trial. Psychother Psychosom. 2011;80:287-97.
  • Machielsen M, Scheltema Beduin A, Dekker N, Kahn RS, Linszen DH, Van Os J, et al. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol. 2011.
  • Zhornitsky S, Rizkallah E, Pampoulova T, Chiasson JP, Stip E, Rompré PP, et al. Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol. 2010;30:417-24.
  • Coyle JT. Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res. 2006;10:221-33.
  • Green B, Kavanagh DJ, Young RM. Predictors of cannabis use in men with and without psychosis. Addict Behav. 2007;32:2879-87.
  • Sundram S, Copolov D, Dean B. Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:428-33.
  • Meltzer HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004;161:975-84.
  • Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2011;31:86-91.

Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol. 2009;23:979-83.

Chemical Review and Letters
Volume 5, Issue 4 - Serial Number 4
Summer 2022
Pages 234-240

  • Receive Date 01 July 2022
  • Revise Date 23 July 2022
  • Accept Date 23 July 2022

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us